Twitter LinkedIn YouTube iTune Podcast Google Podcasts Spotify

StageZero Life Sciences Ltd. TSX: SZLS

InvestorIntel Features on StageZero Life Sciences Ltd.

StageZero’s James Howard-Tripp on diagnosing cancer early

“We are all about finding diseases early. Our current focus is on cancer. If you can find it early your […]

It’s all about detecting cancers early as GeneNews changes name to StageZero Life Sciences

GeneNews Limited (TSX: GEN) has announced that the company will change its name to “StageZero Life Sciences, Ltd.” The Company […]

GeneNews stock is up 177% YTD as their ColonSentry cancer detection kit wins a large agreement

Nothing is more important in life than your health. The early detection of diseases like cancer is improving each decade, […]

Company Overview

TeamWebsite

StageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which was validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer. Further validation of Aristotle is currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancers. To learn more visit www.stagezerolifesciences.com.

News Releases

View All News

Twitter LinkedIn YouTube Amazon Alexa iTune Podcast Google Podcasts Spotify